C Pasien dengan KGB iliaka komunis atau para aorta yang positif sebaiknya
diterapi dengan radiasi dengan lapangan radiasi yang lebih luas baik dengan
atau tanpa kemoterapi.
26
dibandingan dengan wanita tidak hamil. Saat janin dinyatakan viabel, terapi
dengan SC klasik dan diikuti radikal histerektomi dapat dilakukan (secara
umum < 34 mgg kehamilan).
27
WEWANTI (DISCLAIMER)
• Pedoman pelayanan nasional kedokteran untuk kanker Serviks ini hanya berlaku
untuk rumah sakit yang memiliki fasilitas pelayanan onkologi.
• Variasi pelayanan kanker serviks pada setiap tingkat rumah sakit harus
disesuaikan dengan kemampuan fasilitas yang ada.
• Sistem rujukan kasus atau pemeriksaan harus dilaksanakan apabila fasilitas di
rumah sakit tidak dimungkinkan atau tersedia.
• Apabila terdapat keraguan oleh klinisi, agar dapat dilakukan konsultasi dan
diputuskan oleh kelompok pakar sesuai dengan kondisi kasusnya.
28
DAFTAR PUSTAKA
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statis- tics, 2012. CA Cancer J Clin 2015;65(2):87–108.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary
cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.
3. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004.
National Cancer Institute; Bethesda, MD 2007.
5. Ostör AG. Studies on 200 cases of early squamous cell carcinoma of the cervix. Int J
Gynecol Pathol 1993;12(3):193–207.
6. Shepherd JH, Spencer C, Herod J, Ind TE. Radical vaginal trachelectomy as a fertility-
sparing procedure in women with early-stage cervical cancer-cumulative pregnan- cy
rate in a series of 123 women. BJOG 2006;113(6):719–24.
9. Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin Jr JM. Clinical
and histopathologic factors predicting recurrence and survival after pelvic exenteration
for cancer of the cervix. Obstet Gynecol 1989;73(6):1027–34.
11. Coutant C, Cordier AG, Guillo E, Ballester M, Rouzier R, Daraï E. Clues pointing to
simple hysterectomy to treat early-stage cervical cancer. Oncol Rep 2009;22(4): 927–34.
12. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent
chemo- therapy and pelvic radiation therapy compared with pelvic radiation therapy
alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cer-
vix. J Clin Oncol 2000;18(8):1606–13.
29
13. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A
phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical
carcinoma with poor prognostic features: follow-up of a gynecologic oncology group
study. Int J Radiat Oncol Biol Phys 2006;65(1):169–76.
14. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical
car- cinoma metastatic to para-aortic nodes: extended field radiation therapy with con-
comitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group
study. Int J Radiat Oncol Biol Phys 1998;42(5):1015–23.
15. Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, et al. Randomized
trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with
ifosfamide and cisplatin followed by radical surgery in patients with locally ad- vanced
squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian
Collaborative Study. J Clin Oncol 2005;23(18):4137–45.
16. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concur-
rent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
N Engl J Med 1999;340(15):1144–53.
17. Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix
I. Impact of prolongation of overall treatment time and timing of brachytherapy on
outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32(5):1275–88.
19. Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. Follow-up for women
after treatment for cervical cancer: A systematic review. Gynecol Oncol 2009;
114(3):528–35.
20. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al.
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recur- rent,
or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol
2009;27(28):4649–55.
21. Tewari KS, Sill MW, Long 3rd HJ, Penson RT, Huang H, Ramondetta LM, et al. Im-
proved survival with bevacizumab in advanced cervical cancer. N Engl J Med
2014;370(8):734–43.
30
PEDOMAN NASIONAL PELAYANAN KESEHATAN
KANKER ENDOMETRIUM
HOGI
2018
0
DAFTAR KONTRIBUTOR
1
DAFTAR ISI
Contents
Bab I Pendahuluan .................................................................................................................................. 6
1.3 Tujuan...................................................................................................................................... 7
2
3.8 Pemeriksaan Lanjutan dan Manajemen Fertility Preserving Therapy pada Pasien dengan
AH/EIN dan EEC Grade 1 ................................................................................................................ 14
3.17 Penyulit...................................................................................................................................... 22
3.20 Luaran........................................................................................................................................ 23
Bab IV ................................................................................................................................................... 24
4.1.2 Pemeriksaan lanjutan dan skema penatalaksaan untuk fertility preserving therapy pada
pasien dengan hyperplasia atipikal (AH/ neoplasia endometrium epithelial (EIN) dan kanker
endometrioid endometrium (EEC) stadium 1 ............................................................................... 25
4.1.3 Penanda (molekuler) yang dapat membantu untuk membedakan lesi prekanker dengan lesi
jinak yang serupa ........................................................................................................................... 26
3
4.2.3 Pilihan terapi pembedahan radikal untuk stadium dan subtipe patologi yang berbeda pada
kanker endometrium ...................................................................................................................... 29
4.3.2 Terapi adjuvant pada berbagai kelompok risiko kanker endometrium ............................ 30
4.4.3
Targeted agents yang paling menjanjikan dan desain studi yang perlu digunakan untuk
mengevaluasi manfaat klinisnya ................................................................................................... 35
BAB 5…………………………………………………………………………………………………36
Penyangkalan…………………………………………………………………………………36
Daftar Pustaka………………………………………………………………………………...37
Daftar Tabel
Tabel 1. Klasifikasi dan Karakteristik Kanker Endometrium berdasarkan subtipe Bokhman.
Tabel 2. Klasifikasi kanker endometrium menurut FIGO dan TNM berdasarkan karakteristik
operatif dan histologi
Tabel 3. Kelompok risiko pada kanker endometrium. Stadium berdasarkan FIGO 2009.
LVSI: Lymphovascular space invasion